Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters

Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma

(2015) Troels K. Bergmann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic Drug Interaction Studies with Enzalutamide

(2015) Jacqueline A. Gibbons et al.   CLINICAL PHARMACOKINETICS

Nonstatin Therapies for Management of Dyslipidemia: A Review

(2015) Karen R. Sando et al.   CLINICAL THERAPEUTICS

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

(2015) Rajeev M. Menon et al.   JOURNAL OF HEPATOLOGY

Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide

(2015) Emi Kimoto et al.   MOLECULAR PHARMACEUTICS

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

(2015) Aleksi Tornio et al.   Pharmacogenetics and Genomics

Effect of Concomitant Use of Montelukast and Efavirenz on Neuropsychiatric Adverse Events

(2014) Olatz Ibarra-Barrueta et al.   ANNALS OF PHARMACOTHERAPY

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

(2014) A R Tan et al.   BRITISH JOURNAL OF CANCER

Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

(2014) A Tornio et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers

(2014) Sreeraj Macha et al.   CLINICAL THERAPEUTICS

Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib

(2014) A. Benjamin Suttle et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite

(2013) A M Filppula et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

(2013) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11)

(2013) Jenny M. Pedersen et al.   TOXICOLOGICAL SCIENCES

Impact of theCYP2C8*3polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone

(2012) Christina L. Aquilante et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Screening Study of Drug–Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel

(2012) J S Floyd et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

(2012) J Honkalammi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

(2012) Aleksi Tornio et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates

(2011) AM Filppula et al.   BRITISH JOURNAL OF PHARMACOLOGY

Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

(2011) J Honkalammi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations

(2011) A. M. Filppula et al.   DRUG METABOLISM AND DISPOSITION

Studies to Further Investigate the Inhibition of Human Liver Microsomal CYP2C8 by the Acyl- -Glucuronide of Gemfibrozil

(2011) S. M. Jenkins et al.   DRUG METABOLISM AND DISPOSITION

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

(2011) J. Honkalammi et al.   DRUG METABOLISM AND DISPOSITION

Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments

(2011) T. Watanabe et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers

(2011) Arun K. P. et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions

(2011) Maria Karlgren et al.   PHARMACEUTICAL RESEARCH

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

(2011) M. Niemi et al.   PHARMACOLOGICAL REVIEWS

SLCO1B1 Polymorphism and Oral Antidiabetic Drugs

(2010) Annikka Kalliokoski et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism

(2010) Jinping Gan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast

(2010) T Karonen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in Bile and Plasma in Healthy Volunteers

(2010) Ebba Bergman et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin

(2010) Lloyd R. Whitfield et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Benzylic Oxidation of Gemfibrozil-1-O-β-Glucuronide by P450 2C8 Leads to Heme Alkylation and Irreversible Inhibition

(2009) Brian R. Baer et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe

(2009) J. T. Backman et al.   DRUG METABOLISM AND DISPOSITION

Gemfibrozil Concentrations Are Significantly Decreased in the Presence of Lopinavir-Ritonavir

(2009) Kristin H Busse et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo

(2008) A Tornio et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS